Teva Plans Expansion in Asia

Teva is looking towards Asia for acquisitions, hoping to expand into a market where generic use will increase.

Israel-based pharma giant Teva is looking towards Asia for acquisitions, hoping to expand into a market where generic use will increase.

Teva chief financial officer Eyal Desheh highlighted markets in China, India, Vietnam, Korea and the Philippines. "The key is very local businesses," he said at the JP Morgan Global Healthcare Conference in San Francisco, US, "There won't be deals the size of Cephalon, Ratiopharm and Barr, but it's possible to expect smaller acquisitions and acquisitions of products."

Teva was publicising its future strategy against the backdrop of the looming patent expiry of its multiple sclerosis blockbuster Copaxone. The company is also looking to expand its branded business to compensate